ULK1 and non-small cell lung carcinoma: An in vitro study showed increased ULK1 activity and autophagy in KRAS G12C-mutated NSCLC cell lines when treated with KRAS G12C inhibitors, which was suppressed by a ULK1/2 inhibitor.